{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T13:08:22Z","timestamp":1779887302739,"version":"3.53.1"},"reference-count":96,"publisher":"The Journal of Health Economics and Outcomes Research","issue":"1","license":[{"start":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["jheor.org"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec id=\"background\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Duchenne muscular dystrophy (DMD) is a rare, X-linked inherited disorder starting in early childhood, characterized by progressive muscle loss and weakness, causing disability, loss of ambulation, and cardiopulmonary failure. Economic modeling is required to assess cost-effectiveness of new DMD therapies, but there are challenges from limitations and variations in currently available data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"objective\">\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To assess the burden of DMD on patients, caregivers and healthcare systems, identifying inputs for cost-effectiveness models to inform economic assessments.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"methods\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Two systematic literature reviews (SLRs) were conducted. One SLR was performed to identify health state utility values (HSUV, original date 2019 with a 2023 update) and another to identify and cost data (original date 2023). Both SLRs were updated in 2024. Databases searched included Embase, MEDLINE, Centre for Reviews and Dissemination and EconLit, with additional hand-searching. PRISMA guidelines were followed. For each SLR, title\/abstract and full-text screening were performed by two independent reviewers before data extraction. Validated quality assessment tools were used.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"results\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Across both SLRs, the burden increased as DMD progressed from early to late stages, indicated by decreasing HSUVs and increasing healthcare resource use and costs. The results highlighted large increases in burdens between early nonambulatory and late nonambulatory DMD in studies using the typical 4-state progression model. Recent publications using an 8-stage natural history model reported gradual increases in burden. There was heterogeneity between studies and a lack of long-term data in both SLRs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"discussion\">\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>The results highlighted the complex nature of progressive DMD, with heterogeneity and lack of long-term data across the studies. The findings suggest that HUI-3 may be the preferred tool for HSUV measurement in DMD, and the 8-stage natural history model may be preferable to typical 4-state models of DMD progression, to account for the observed heterogeneity and non-linear progression of this rare disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"conclusions\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These data indicate that the burden on patients, caregivers, and healthcare systems increases as DMD progresses. A wide range of inputs for economic modeling were identified, including insights into the way that the stages of DMD should be modeled to accurately reflect progression.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.36469\/001c.158537","type":"journal-article","created":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:39:51Z","timestamp":1777387191000},"update-policy":"https:\/\/doi.org\/10.36469\/00001","source":"Crossref","is-referenced-by-count":0,"title":["Systematic Literature Reviews of Health-State Utility Values, Costs, and Healthcare Resource Use in Duchenne Muscular Dystrophy"],"prefix":"10.36469","volume":"13","author":[{"given":"Chui-ying","family":"Yip","sequence":"first","affiliation":[{"name":"F. Hoffmann-La Roche Ltd, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric N.","family":"Kemadjou","sequence":"additional","affiliation":[{"name":"F. Hoffmann-La Roche Ltd, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisy","family":"Stewart","sequence":"additional","affiliation":[{"name":"Source Health Economics, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Shapiro","sequence":"additional","affiliation":[{"name":"Source Health Economics, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Macmillan","sequence":"additional","affiliation":[{"name":"Source Health Economics, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"22273","published-online":{"date-parts":[[2026,4,28]]},"reference":[{"issue":"8","key":"ref1","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1111\/j.1440-1754.2011.02022.x","article-title":"Health status of boys with Duchenne muscular dystrophy: a parent's perspective","volume":"47","author":"P. Bray","year":"2011","journal-title":"J Paediatr Child Health"},{"issue":"10","key":"ref2","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1111\/dmcn.13934","article-title":"Duchenne muscular dystrophy and caregiver burden: a systematic review","volume":"60","author":"E. Landfeldt","year":"2018","journal-title":"Dev Med Child Neurol"},{"issue":"5","key":"ref3","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1111\/dmcn.12938","article-title":"Health-related quality of life in patients with Duchenne muscular dystrophy: a multinational, cross-sectional study","volume":"58","author":"E. Landfeldt","year":"2016","journal-title":"Dev Med Child Neurol"},{"issue":"4","key":"ref4","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.apmr.2006.12.032","article-title":"Response shift theory: important implications for measuring quality of life in people with disability","volume":"88","author":"C. E. Schwartz","year":"2007","journal-title":"Arch Phys Med Rehabil"},{"issue":"1","key":"ref5","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s13023-023-02674-w","article-title":"Toward patient-centered treatment goals for Duchenne muscular dystrophy: insights from the \"Your Voice\" study","volume":"18","author":"C. E. Schwartz","year":"2023","journal-title":"Orphanet J Rare Dis"},{"issue":"S 01","key":"ref6","doi-asserted-by":"publisher","first-page":"A","DOI":"10.1055\/s-0045-1812126","article-title":"The societal costs of Duchenne muscular dystrophy in Germany","volume":"56","author":"T. Hackmann","year":"2025","journal-title":"Neuropediatrics"},{"issue":"4","key":"ref7","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/s1474-4422(18)30025-5","article-title":"Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management","volume":"17","author":"D. J. Birnkrant","year":"2018","journal-title":"Lancet Neurol"},{"issue":"6","key":"ref8","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1212\/WNL.0000000000000669","article-title":"The burden of Duchenne muscular dystrophy","volume":"83","author":"E. Landfeldt","year":"2014","journal-title":"Neurology"},{"issue":"12","key":"ref9","doi-asserted-by":"publisher","first-page":"S90","DOI":"10.1016\/j.jval.2022.09.440","article-title":"EE190 Association of total annual costs of Duchenne muscular dystrophy with disease severity","volume":"25","author":"A. Vavrovsky","year":"2022","journal-title":"Value Health"},{"issue":"3","key":"ref10","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/s1474-4422(18)30024-3","article-title":"Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management","volume":"17","author":"D. J. Birnkrant","year":"2018","journal-title":"Lancet Neurol"},{"issue":"6","key":"ref11","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/0092-8674(87)90579-4","article-title":"Dystrophin: the protein product of the Duchenne muscular dystrophy locus","volume":"51","author":"E. P. Hoffman","year":"1987","journal-title":"Cell"},{"issue":"5","key":"ref12","doi-asserted-by":"publisher","first-page":"Cd003725","DOI":"10.1002\/14651858.CD003725.pub4","article-title":"Corticosteroids for the treatment of Duchenne muscular dystrophy","volume":"2016","author":"E. Matthews","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"ref13","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15030778","article-title":"Recent trends in antisense therapies for Duchenne muscular dystrophy","volume":"15","author":"H. Wilton-Clark","year":"2023","journal-title":"Pharmaceutics"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"833833","DOI":"10.3389\/fbioe.2022.833833","article-title":"A decade of progress in gene targeted therapeutic strategies in Duchenne muscular dystrophy: a systematic review","volume":"10","author":"L. Chung Liang","year":"2022","journal-title":"Front Bioeng Biotechnol"},{"issue":"10","key":"ref15","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1080\/14737175.2023.2249607","article-title":"Gene therapy for Duchenne muscular dystrophy: an update on the latest clinical developments","volume":"23","author":"C. Happi Mbakam","year":"2023","journal-title":"Expert Rev Neurother"},{"issue":"3","key":"ref16","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1007\/s11136-019-02355-x","article-title":"Characterizing health state utilities associated with Duchenne muscular dystrophy: a systematic review","volume":"29","author":"S. M. Szabo","year":"2020","journal-title":"Qual Life Res"},{"issue":"8","key":"ref17","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1001\/archneur.1987.00520200016010","article-title":"Clinical investigation of Duchenne muscular dystrophy. Interesting results in a trial of prednisone","volume":"44","author":"M. H. Brooke","year":"1987","journal-title":"Arch Neurol"},{"issue":"4","key":"ref18","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/j.jval.2013.02.017","article-title":"Systematic searching and selection of health state utility values from the literature","volume":"16","author":"D. Papaioannou","year":"2013","journal-title":"Value Health"},{"issue":"5","key":"ref19","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1111\/j.1524-4733.2008.00327.x","article-title":"Methodological considerations in cost of prostate cancer studies: a systematic review","volume":"11","author":"L. Molinier","year":"2008","journal-title":"Value Health"},{"issue":"3","key":"ref20","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1002\/mus.26109","article-title":"Psychometric analysis of the pediatric quality of life inventory 3.0 neuromuscular module administered to patients with Duchenne muscular dystrophy: a Rasch analysis","volume":"58","author":"E. Landfeldt","year":"2018","journal-title":"Muscle Nerve"},{"issue":"suppl 12","key":"ref21","doi-asserted-by":"publisher","first-page":"S486","DOI":"10.1016\/j.jval.2023.09.2629","article-title":"PCR192 Content validity of the EQ-5D and Health Utilities Index (HUI) to assess health-related quality-of-life (HRQoL) impact in Duchenne muscular dystrophy (DMD)","volume":"26","author":"S. Szabo","year":"2023","journal-title":"Value Health"},{"issue":"1","key":"ref22","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s13023-020-01430-8","article-title":"Global epidemiology of Duchenne muscular dystrophy: an updated systematic review and meta-analysis","volume":"15","author":"S. Crisafulli","year":"2020","journal-title":"Orphanet J Rare Dis"},{"issue":"6","key":"ref23","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1007\/s00246-018-1889-5","article-title":"Cost-effectiveness of ventricular assist device destination therapy for advanced heart failure in Duchenne muscular dystrophy","volume":"39","author":"D. A. Magnetta","year":"2018","journal-title":"Pediatr Cardiol"},{"issue":"1","key":"ref24","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s12955-022-01941-x","article-title":"Quality of life and informal care burden associated with Duchenne muscular dystrophy in Portugal: the COIDUCH study","volume":"20","author":"V. Andreozzi","year":"2022","journal-title":"Health Qual Life Outcomes"},{"issue":"suppl 7","key":"ref25","doi-asserted-by":"publisher","first-page":"S574","DOI":"10.1016\/j.jval.2022.04.1519","article-title":"Time trade-off utility values for health states characterizing progressive muscular degeneration in Duchenne muscular dystrophy (DMD)","volume":"25","author":"F. I. Audhya","year":"2022","journal-title":"Value Health"},{"issue":"suppl 6","key":"ref26","doi-asserted-by":"publisher","first-page":"S355","DOI":"10.1016\/j.jval.2023.03.2772","article-title":"Estimating utility values using the Duchenne Muscular Dystrophy-Quality of Life Measure (DMD-QOL): a new preference-based measure for Duchenne muscular dystrophy","volume":"26","author":"A. Bever","year":"2023","journal-title":"Value Health"},{"issue":"2","key":"ref27","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1177\/0272989X20978390","article-title":"Assessing the appropriateness of the EQ-5D for Duchenne muscular dystrophy: a patient-centered study","volume":"41","author":"N. L. Crossnohere","year":"2021","journal-title":"Med Decis Making"},{"issue":"3","key":"ref28","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1002\/mus.26787","article-title":"Improvements in health status and utility associated with ataluren for the treatment of nonsense mutation Duchenne muscular dystrophy","volume":"61","author":"E. Landfeldt","year":"2020","journal-title":"Muscle Nerve"},{"issue":"1","key":"ref29","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1080\/13696998.2022.2085444","article-title":"Assessment of face validity of a disease model of nonsense mutation Duchenne muscular dystrophy: a multi-national Delphi panel study","volume":"25","author":"E. Landfeldt","year":"2022","journal-title":"J Med Econ"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.vhri.2022.08.006","article-title":"Estimating societal cost of illness and patients' quality of life of Duchenne muscular dystrophy in Egypt","volume":"33","author":"Z. H. Shehata","year":"2023","journal-title":"Value Health Reg Issues"},{"issue":"suppl 6","key":"ref31","doi-asserted-by":"publisher","first-page":"S7","DOI":"10.1016\/j.jval.2023.03.043","article-title":"The association between patient- and caregiver-reported utility values in Duchenne muscular dystrophy (DMD)","volume":"26","author":"S. Szabo","year":"2023","journal-title":"Value Health"},{"issue":"12 suppl","key":"ref32","doi-asserted-by":"publisher","first-page":"S68","DOI":"10.1016\/j.jval.2023.09.363","article-title":"Introduction to the Duchenne Muscular Dystrophy Burden-of-Illness Study Expanded (US and Spain)","volume":"26","author":"D. Castro","year":"2023","journal-title":"Value Health"},{"issue":"6","key":"ref33","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/j.ejpn.2016.07.020","article-title":"Why are some patients with Duchenne muscular dystrophy dying young: an analysis of causes of death in North East England","volume":"20","author":"H. J. A. Van Ruiten","year":"2016","journal-title":"Eur J Paediatr Neurol"},{"issue":"10","key":"ref34","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1016\/j.jval.2021.03.007","article-title":"Deriving a preference-based measure for people with Duchenne muscular dystrophy from the DMD-QoL","volume":"24","author":"D. Rowen","year":"2021","journal-title":"Value Health"},{"issue":"1","key":"ref35","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s10198-023-01574-x","article-title":"Assessing validity of the EQ-5D-5L proxy in children and adolescents with Duchenne muscular dystrophy or spinal muscular atrophy","volume":"25","author":"R. H. Xu","year":"2024","journal-title":"Eur J Health Econ"},{"issue":"suppl 1","key":"ref36","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s10198-016-0782-5","article-title":"Social\/economic costs and health-related quality of life in patients with Duchenne muscular dystrophy in Europe","volume":"17","author":"M. Cavazza","year":"2016","journal-title":"Eur J Health Econ"},{"issue":"12","key":"ref37","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/j.nmd.2015.09.012","article-title":"Development and psychometric analysis of the Duchenne Muscular Dystrophy Function Ability Self-Assessment Tool (DMDSAT)","volume":"25","author":"E. Landfeldt","year":"2015","journal-title":"Neuromuscul Disord"},{"issue":"12","key":"ref38","doi-asserted-by":"publisher","first-page":"988","DOI":"10.3109\/09638288.2011.628738","article-title":"Subjective caregiver burden of parents of adults with Duchenne muscular dystrophy","volume":"34","author":"R. F. Pangalila","year":"2012","journal-title":"Disabil Rehabil"},{"issue":"suppl 2","key":"ref39","doi-asserted-by":"publisher","first-page":"S602","DOI":"10.1016\/j.jval.2020.08.1192","article-title":"Estimation of health utilities for nonambulatory Duchenne muscular dystrophy (DMD) patients and their caregivers","volume":"23","author":"K. Gallop","year":"2020","journal-title":"Value Health"},{"issue":"5","key":"ref40","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1007\/s00415-016-8080-9","article-title":"Quantifying the burden of caregiving in Duchenne muscular dystrophy","volume":"263","author":"E. Landfeldt","year":"2016","journal-title":"J Neurol"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1186\/s41687-023-00671-y","article-title":"Estimating health state utilities in Duchenne muscular dystrophy (DMD) using the EQ-5D and Health Utilities Index (HUI)","author":"I. Audhya","year":"2022","journal-title":"Annual Congress of the World Muscle Society"},{"issue":"4","key":"ref42","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1212\/CPJ.0000000000000970","article-title":"Achieving life milestones in Duchenne\/Becker muscular dystrophy: a retrospective analysis","volume":"11","author":"A. Donaldson","year":"2021","journal-title":"Neurol Clin Pract"},{"issue":"suppl 6","key":"ref43","doi-asserted-by":"publisher","first-page":"S96","DOI":"10.1016\/j.jval.2023.03.505","article-title":"All-cause healthcare costs by race among Medicaid-insured males with Duchenne muscular dystrophy using U.S. real-world data","volume":"26","author":"N. Posner","year":"2023","journal-title":"Value Health"},{"issue":"7","key":"ref44","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1007\/s10654-020-00613-8","article-title":"Life expectancy at birth in Duchenne muscular dystrophy: a systematic review and meta-analysis","volume":"35","author":"E. Landfeldt","year":"2020","journal-title":"Eur J Epidemiol"},{"issue":"1","key":"ref45","doi-asserted-by":"publisher","first-page":"2216518","DOI":"10.1080\/20016689.2023.2216518","article-title":"Assessing the value of delandistrogene moxeparvovec (SRP-9001) gene therapy in patients with Duchenne muscular dystrophy in the United States","volume":"11","author":"A. C. Klimchak","year":"2023","journal-title":"J Mark Access Health Policy"},{"key":"ref46","article-title":"Ataluren (Translarna\u00ae) for Duchenne muscular dystrophy (SMC2327)","author":"Scottish Medicines Consortium (SMC)"},{"key":"ref47","article-title":"Ataluren for treating Duchenne muscular dystrophy caused by a nonsense mutation in the dystrophin gene. Highly specialised technologies guidance (HST3) [ID 428]","author":"National Institute for Health and Care Excellence (NICE)"},{"key":"ref48","article-title":"Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene. Highly specialised technologies guidance (HST22) [ID1642]","author":"National Institute for Health and Care Excellence (NICE)"},{"issue":"10","key":"ref49","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.18553\/jmcp.2021.27.10.1426","article-title":"Characterizing demographics, comorbidities, and costs of care among populations with Duchenne muscular dystrophy with Medicaid and commercial coverage","volume":"27","author":"A. C. Klimchak","year":"2021","journal-title":"J Manag Care Spec Pharm"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s13023-014-0210-9","article-title":"Comparative cost of illness analysis and assessment of health care burden of Duchenne and Becker muscular dystrophies in Germany","volume":"9","author":"O. Schreiber-Katz","year":"2014","journal-title":"Orphanet J Rare Dis"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"63","DOI":"10.3233\/JND-140053","article-title":"Compliance to care guidelines for Duchenne muscular dystrophy","volume":"2","author":"E. Landfeldt","year":"2015","journal-title":"J Neuromuscul Dis"},{"issue":"12","key":"ref52","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1007\/s10554-019-01670-1","article-title":"Conservative gadolinium administration to patients with Duchenne muscular dystrophy: decreasing exposure, cost, and time, without change in medical management","volume":"35","author":"S. M. Lang","year":"2019","journal-title":"Int J Cardiovasc Imaging"},{"issue":"6","key":"ref53","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1097\/PHM.0000000000000228","article-title":"Cost and physician effort analysis of invasive vs. noninvasive respiratory management of Duchenne muscular dystrophy","volume":"94","author":"J. R. Bach","year":"2015","journal-title":"Am J Phys Med Rehabil"},{"issue":"9","key":"ref54","doi-asserted-by":"publisher","first-page":"E884","DOI":"10.1212\/WNL.0000000000201627","article-title":"Costs and utilization of new-to-market neurologic medications","volume":"100","author":"E. L. Reynolds","year":"2023","journal-title":"Neurology"},{"issue":"1","key":"ref55","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/s1474-4422(09)70271-6","article-title":"Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management","volume":"9","author":"K. Bushby","year":"2010","journal-title":"Lancet Neurol"},{"issue":"5","key":"ref56","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1007\/s00246-021-02807-7","article-title":"Current practices in treating cardiomyopathy and heart failure in Duchenne muscular dystrophy (DMD): understanding care practices in order to optimize DMD heart failure through ACTION","volume":"43","author":"C. Villa","year":"2022","journal-title":"Pediatr Cardiol"},{"key":"ref57","first-page":"115","article-title":"Deflazacort, eteplirsen, and golodirsen for Duchenne muscular dystrophy: effectiveness and value-evidence report","author":"G. Lin","year":"2019"},{"issue":"10","key":"ref58","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.5664\/jcsm.9400","article-title":"Determinants of usage and nonadherence to noninvasive ventilation in children and adults with Duchenne muscular dystrophy","volume":"17","author":"M. S. Hurvitz","year":"2021","journal-title":"J Clin Sleep Med"},{"issue":"6","key":"ref59","doi-asserted-by":"publisher","first-page":"633","DOI":"10.18553\/jmcp.2017.23.6.633","article-title":"The direct cost of managing a rare disease: assessing medical and pharmacy costs associated with Duchenne muscular dystrophy in the United States","volume":"23","author":"S. Thayer","year":"2017","journal-title":"J Manag Care Spec Pharm"},{"issue":"5","key":"ref60","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1002\/mus.27505","article-title":"Direct costs of adhering to selected Duchenne muscular dystrophy care considerations: estimates from a Midwestern state","volume":"65","author":"K. M. Conway","year":"2022","journal-title":"Muscle Nerve"},{"issue":"6","key":"ref61","doi-asserted-by":"publisher","first-page":"2906","DOI":"10.1007\/s12325-022-02117-1","article-title":"Disease progression stages and burden in patients with Duchenne muscular dystrophy using administrative claims supplemented by electronic medical records","volume":"39","author":"J. Iff","year":"2022","journal-title":"Adv Ther"},{"issue":"suppl 1","key":"ref62","doi-asserted-by":"publisher","first-page":"S131","DOI":"10.1016\/j.nmd.2020.08.288","article-title":"DMD - THERAPY: P.291 Real-world evidence of eteplirsen treatment effects on Duchenne muscular dystrophy related health outcomes using claims data in the United States","volume":"30","author":"J. Iff","year":"2020","journal-title":"Neuromuscul Disord"},{"issue":"2","key":"ref63","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s40273-016-0461-5","article-title":"Economic evaluation in Duchenne muscular dystrophy: model frameworks for cost-effectiveness analysis","volume":"35","author":"E. Landfeldt","year":"2017","journal-title":"PharmacoEconomics"},{"issue":"6","key":"ref64","doi-asserted-by":"publisher","first-page":"S133","DOI":"10.1016\/j.jval.2023.03.702","article-title":"EE401 Characterizing the impact on work productivity in patients with Duchenne muscular dystrophy and caregivers: an economic analysis","volume":"26","author":"B. Innis","year":"2023","journal-title":"Value Health"},{"issue":"12","key":"ref65","doi-asserted-by":"publisher","first-page":"S158","DOI":"10.1016\/j.jval.2022.09.764","article-title":"EE523 Assessing the economic and quality of life impact of treatment in Duchenne muscular dystrophy","volume":"25","author":"D. Mujwara","year":"2022","journal-title":"Value Health"},{"issue":"3","key":"ref66","doi-asserted-by":"publisher","first-page":"579","DOI":"10.3233\/jnd-230220","article-title":"Predictors of loss of ambulation in Duchenne muscular dystrophy: a systematic review and meta-analysis","volume":"11","author":"E. Landfeldt","year":"2024","journal-title":"J Neuromuscul Dis"},{"issue":"4","key":"ref67","doi-asserted-by":"publisher","first-page":"517","DOI":"10.3233\/JND-160185","article-title":"European cross-sectional survey of current care practices for Duchenne muscular dystrophy reveals regional and age-dependent differences","volume":"3","author":"J. Vry","year":"2016","journal-title":"J Neuromuscul Dis"},{"issue":"suppl 12","key":"ref68","doi-asserted-by":"publisher","first-page":"S476","DOI":"10.1016\/j.jval.2023.09.2580","article-title":"The impact of Duchenne muscular dystrophy on caregiver employment: a survey in Europe, Japan, and the United States","volume":"26","author":"J. Strober","year":"2023","journal-title":"Value Health"},{"issue":"6","key":"ref69","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1002\/mus.27429","article-title":"Labor market participation and productivity costs for female caregivers of minor male children with Duchenne and Becker muscular dystrophies","volume":"64","author":"R. H. Soelaeman","year":"2021","journal-title":"Muscle Nerve"},{"issue":"suppl 6","key":"ref70","doi-asserted-by":"publisher","first-page":"S248","DOI":"10.1016\/j.jval.2023.03.1366","article-title":"Medical chart audit study to demonstrate shortcomings of corticosteroids in treatment of Duchenne muscular dystrophy","volume":"26","author":"T. White","year":"2023","journal-title":"Value Health"},{"issue":"1","key":"ref71","doi-asserted-by":"publisher","first-page":"e100","DOI":"10.5301\/grhta.5000260","article-title":"Mortality cost of Duchenne muscular dystrophy","volume":"4","author":"E. Landfeldt","year":"2017","journal-title":"Glob Reg Health Technol Assess"},{"issue":"12","key":"ref72","doi-asserted-by":"publisher","first-page":"e3331","DOI":"10.1002\/brb3.3331","article-title":"Natural history of Duchenne muscular dystrophy in the United Kingdom: a descriptive study using the Clinical Practice Research Datalink","volume":"13","author":"J. Broomfield","year":"2023","journal-title":"Brain Behav"},{"issue":"3","key":"ref73","first-page":"136","article-title":"Psychological and practical difficulties among parents and healthy siblings of children with Duchenne vs. Becker muscular dystrophy: an Italian comparative study","volume":"33","author":"L. Magliano","year":"2014","journal-title":"Acta Myol"},{"issue":"7","key":"ref74","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1007\/s10198-020-01197-6","article-title":"Quantifying the economic impact of caregiving for Duchenne muscular dystrophy (DMD) in Spain","volume":"21","author":"D. Flores","year":"2020","journal-title":"Eur J Health Econ"},{"issue":"9","key":"ref75","doi-asserted-by":"publisher","first-page":"e230086","DOI":"10.57264\/cer-2023-0086","article-title":"Real-world evidence of eteplirsen treatment effects in patients with Duchenne muscular dystrophy in the USA","volume":"12","author":"J. Iff","year":"2023","journal-title":"J Comp Eff Res"},{"issue":"19","key":"ref76","doi-asserted-by":"publisher","first-page":"12334","DOI":"10.3390\/ijerph191912334","article-title":"The role of associations in reducing the emotional and financial impact on parents caring for children with Duchenne muscular dystrophy: a cross-cultural study","volume":"19","author":"A. A. Rodriguez","year":"2022","journal-title":"Int J Environ Res Public Health"},{"issue":"1","key":"ref77","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s41669-023-00450-x","article-title":"Developing a natural history model for Duchenne muscular dystrophy","volume":"8","author":"J. Broomfield","year":"2024","journal-title":"Pharmacoecon Open"},{"issue":"3","key":"ref78","doi-asserted-by":"publisher","first-page":"553","DOI":"10.3233\/PRM-220026","article-title":"Use of supported standing in males with Duchenne muscular dystrophy: individual and family perspectives","volume":"16","author":"K. Bonarrigo","year":"2023","journal-title":"J Pediatr Rehabil Med"},{"issue":"2","key":"ref79","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1177\/0272989x211062237","article-title":"Measuring what matters: little evidence supporting the content validity of EQ-5D in people with Duchenne muscular dystrophy and their caregivers","volume":"42","author":"P. A. Powell","year":"2022","journal-title":"Med Decis Making"},{"issue":"1","key":"ref80","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s12955-024-02287-2","article-title":"Cataloging health state utility estimates for Duchenne muscular dystrophy and related conditions","volume":"22","author":"L. A. Do","year":"2024","journal-title":"Health Qual Life Outcomes"},{"issue":"10","key":"ref81","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1177\/0883073809357624","article-title":"Health-related quality of life in boys with Duchenne muscular dystrophy: agreement between parents and their sons","volume":"25","author":"P. Bray","year":"2010","journal-title":"J Child Neurol"},{"issue":"11","key":"ref82","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1016\/j.nmd.2021.06.001","article-title":"Health related quality of life in young, steroid-na\u00efve boys with Duchenne muscular dystrophy","volume":"31","author":"C. Campbell","year":"2021","journal-title":"Neuromuscul Disord"},{"issue":"7","key":"ref83","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1007\/s11136-014-0642-7","article-title":"The level of agreement between child self-reports and parent proxy-reports of health-related quality of life in boys with Duchenne muscular dystrophy","volume":"23","author":"Y. Lim","year":"2014","journal-title":"Qual Life Res"},{"issue":"1","key":"ref84","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1186\/s13023-024-03481-7","article-title":"Quality of life and caregiving burden associated with parenting a person with Duchenne\/Becker muscular dystrophy in Poland","volume":"19","author":"J. Domaradzki","year":"2024","journal-title":"Orphanet J Rare Dis"},{"issue":"3","key":"ref85","doi-asserted-by":"publisher","first-page":"100209","DOI":"10.1016\/j.apro.2025.100209","article-title":"The EQ-5D and Health Utilities Index for assessing health-related quality-of-life impact in Duchenne muscular dystrophy: evaluating the relevance and interpretation of descriptive systems from patient and caregiver perspectives","volume":"1","author":"S. M. Szabo","year":"2025","journal-title":"Adv Patient Rep Outcomes"},{"issue":"5","key":"ref86","doi-asserted-by":"publisher","first-page":"e70431","DOI":"10.1111\/hex.70431","article-title":"A qualitative examination of the content validity of the EQ-5D-5L and EQ-5D-Y-3L in adult and paediatric patients with Duchenne muscular dystrophy","volume":"28","author":"R. H. Xu","year":"2025","journal-title":"Health Expect"},{"issue":"1","key":"ref87","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s44162-024-00044-z","article-title":"Epidemiology and healthcare resource utilisation associated with Duchenne muscular dystrophy","volume":"3","author":"C. L. Morgan","year":"2024","journal-title":"J Rare Dis"},{"issue":"1","key":"ref88","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/s41572-021-00248-3","article-title":"Duchenne muscular dystrophy","volume":"7","author":"D. Duan","year":"2021","journal-title":"Nat Rev Dis Primers"},{"issue":"2","key":"ref89","doi-asserted-by":"publisher","first-page":"205","DOI":"10.18553\/jmcp.2025.31.2.205","article-title":"Real-world treatment and health care utilization among patients with Duchenne muscular dystrophy by race and ethnicity in a Medicaid population","volume":"31","author":"N. Posner","year":"2025","journal-title":"J Manag Care Spec Pharm"},{"issue":"2","key":"ref90","doi-asserted-by":"publisher","first-page":"443","DOI":"10.3233\/jnd-230133","article-title":"Burden of disease of Duchenne muscular dystrophy in Denmark - a National Register-based study of individuals with Duchenne muscular dystrophy and their closest relatives","volume":"11","author":"J. H. Rudolfsen","year":"2024","journal-title":"J Neuromuscul Dis"},{"issue":"1","key":"ref91","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1186\/s13023-025-03906-x","article-title":"Epidemiology, disease burden and costs of Duchenne muscular dystrophy in Germany: an observational, retrospective health claims data analysis","volume":"20","author":"J. Diesing","year":"2025","journal-title":"Orphanet J Rare Dis"},{"issue":"6","key":"ref92","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/s40290-025-00587-6","article-title":"The utilization, reimbursement, and cost of targeted therapies for Duchenne muscular dystrophy (DMD) in US Medicaid programs: a descriptive trend analysis from 2017 to 2022","volume":"39","author":"Y. Ghawaa","year":"2025","journal-title":"Pharmaceut Med"},{"issue":"1","key":"ref93","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1186\/s13023-025-03794-1","article-title":"Household costs in the United States for accommodating functional impairments associated with Duchenne muscular dystrophy: results from a caregiver survey","volume":"20","author":"B. Innis","year":"2025","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"ref94","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1002\/sim.9949","article-title":"Modeling the multi-state natural history of rare diseases with heterogeneous individual patient data: a simulation study","volume":"43","author":"J. Broomfield","year":"2024","journal-title":"Stat Med"},{"key":"ref95","article-title":"Ataluren for treating Duchenne muscular dystrophy caused by a nonsense mutation in the dystrophin gene. Highly specialised technologies guidance (HST3) [ID 428]","author":"National Institute for Health and Care Excellence (NICE)"},{"issue":"1","key":"ref96","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1038\/s41467-025-56644-w","article-title":"Duchenne muscular dystrophy: recent insights in brain related comorbidities","volume":"16","author":"C. Vaillend","year":"2025","journal-title":"Nature Commun"}],"container-title":["Journal of Health Economics and Outcomes Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jheor.org\/article\/158537-systematic-literature-reviews-of-health-state-utility-values-costs-and-healthcare-resource-use-in-duchenne-muscular-dystrophy","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T12:35:50Z","timestamp":1779885350000},"score":1,"resource":{"primary":{"URL":"https:\/\/jheor.org\/article\/158537-systematic-literature-reviews-of-health-state-utility-values-costs-and-healthcare-resource-use-in-duchenne-muscular-dystrophy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,28]]},"references-count":96,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.36469\/001c.158537","relation":{},"ISSN":["2327-2236"],"issn-type":[{"value":"2327-2236","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,28]]}}}